Target intelligence / Profile preview

Cullin-1 (CUL1)

Target
CUL1
Molecular classification
E3 ubiquitin ligase scaffold protein, Component of the SCF (SKP1-CUL1-F-box) complex, Other (Cullin protein family)
01

Overview

Cullin-1 is a highly conserved scaffold protein and the central component of the SCF (SKP1-CUL1-F-box) E3 ubiquitin ligase complex, a major regulator of protein degradation via the ubiquitin-proteasome system[1][4]. The SCF complex targets numerous regulatory proteins, including those controlling cell cycle progression (e.g., cyclins, p27), signal transduction, transcription, and primary ciliogenesis, thereby coordinating processes ranging from cell division and differentiation to chromosome maintenance and gene expression[1][3][4][5]. CUL1 undergoes neddylation, which is essential for its E3 ligase activity[1][2][4]. Abnormal CUL1 function is implicated in cancer, certain ciliopathies, neurodegenerative disease, and pathogen-host interactions, reflecting its fundamental biological roles and potential as a therapeutic target[3][4][5].

Other names
Cullin 1CUL1CUL-1cullin-1Lin-19-likeLin-19
02

Mechanism of action

Inhibitors of neddylation (e.g., pevonedistat) inactivate cullin-RING ligases by preventing neddylation of CUL1 and similar proteins, thereby blocking substrate ubiquitination and downstream proteasomal degradation[1][4]. Molecules targeting the assembly or function of the SCF complex affect degradation of cell cycle regulators, leading to cell cycle arrest or apoptosis[1][4].

03

Biological functions

Protein ubiquitinationProtein degradationCell cycle regulationSignal transductionTranscription regulationPrimary ciliogenesis
04

Disease associations

CancerCiliopathiesNeurodegenerative diseaseInfection (including parasitism)
05

Safety considerations

Targeting CUL1 or its pathway can disrupt normal protein turnover, leading to global cellular stress or toxicity[1][4][5].Inhibition of cullin-RING ligases may compromise cell cycle control, provoke cytopenias, or cause off-target effects in normal proliferating tissues[1][5].
06

Interacting drugs

None currently identified as direct CUL1 inhibitors; indirect modulators include neddylation inhibitors like MLN4924 (pevonedistat), which target the activity of the cullin-RING ligase complexes[1][4].
07

Biomarkers

Overexpression or altered neddylation state of CUL1 or SCF components (e.g., SKP2, p27) may serve as biomarkers in cancer and potentially for cell cycle-related therapies[1][4][5].

Beyond the preview

Go deeper on Cullin-1 (CUL1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cullin-1 (CUL1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call